丁苯酞与依达拉奉联用治疗急性进展性缺血性脑卒中的疗效

目的 探讨丁苯酞注射液与依达拉奉联用治疗急性进展性缺血性脑卒中的临床效果。方法 选取急性进展性缺血性脑卒中患者 90 例，随机分为常规组、对照组和观察组，每组 30 例，常规组给予缺血性脑血管病常规治疗，对照组在常规组治疗的基础上给予依达拉奉治疗，观察组在常规组治疗的基础上给予依达拉奉与丁苯酞注射液联用治疗，3 组均连续治疗 14 d。比较 3 组患者治疗前后的神经功能损伤评分（NIHSS）、日常生活能力评分（Barthel 指数），并观察3 组间临床疗效及不良反应。结果3 组在治疗 14 d 后 NIHSS 评分和 Barthel 指数评分较治疗前改善，差异有统计学意义（F=7.652，14.102，P<0.01），且观察组明显优于常规组及对照组，差异有统计学意义（P<0.05）。观察组临床总有效率为 86.67%，明显优于常规组（43.33%）及对照组（60.00%），差异有统计学意义（H=12.243，P=0.002），均未见明显不良反应发生。结论 丁苯酞注射液与依达拉奉联用治疗急性进展性缺血性脑卒中可有效改善神经功能损伤，提高患者的日常生活能力，临床疗效肯定，不良反应少，值得在临床中推广应用。

Clinical curative observation of butylphthalide injection combined with edaravone in the treatment of acute progressive cerebral ischemic stroke

Objective To investigate the clinical effects of butylphthalide injection combined with edaravone in the treatment of progressive cerebral ischemic stroke. Methods 90 patients with progressive cerebral ischemic stroke were divided randomly into three groups, 30 patients in each group. Patients in conventional group were given conventional treatment of ischemic cerebrovascular disease. Patients in control group were treated with edaravone on the basis of conventional treatment. Patients in observed group were given butylphthalide and edaravone on the basis of conventional treatment additionally. The three groups were treated continuously for 14 days. The degree of neurological deficit score (NIHSS) and daily life ability score (Barthel index) were compared respectively among the three groups just before and after treatment. Meanwhile compared the clinical effects and adverse reactions among the three groups.Results Both NIHSS and BI of the three groups were improved following the 14d treatment (F=7.652, 14.102, P<0.01), and the observation group was significantly better than the conventional group and the control group. The difference was statistically significant (P<0.05). The total efficiency of the observation group was 86.67%, which was obviously better than that of the conventional group(43.33%) and the control group (60.00%), the difference was statistically significant (H=12.243, P=0.002). No obvious adverse reaction occurred in the three groups.Conclusion Butylphthalide injection combined with edaravone in the treatment of progressive cerebral ischemic stroke can effectively alleviate nerve function damage, improve the ability of the patients’ daily life, which has higher clinical curative effects and less adverse reactions, is worth popularizing in clinical practices.